‍‘I CAN’ Live with IgAN - but I Won't Let it Define Me.
If you have IgA nephropathy (IgAN), you may be eligible to participate in the
I CAN Study - exploring new options to help protect kidney function.
What Makes This Study Different?
You Can be part of shaping what comes next for your IgAN community.
The I CAN Study was designed with feedback from patients living with IgAN and from the broader IgAN community. Being part of this study means helping researchers learn more about IgAN.
I'm Interested
What is the Purpose of the I CAN Study?
The study aims to evaluate the safety and effectiveness of a study drug, called ravulizumab, compared with placebo to potentially help reduce symptoms of IgAN.
Get Started
Can I Participate?
You may be eligible to participate in this study if you:
Are 18 years of age or older
Were diagnosed with IgA nephropathy
Have protein in your urine. Your doctor may call this “proteinuria.”
Are taking stable kidney medications for 3+ months
You may not be eligible to participate in this study if you had a kidney transplant.
No insurance is needed to join this research study. Other eligibility criteria apply and will be evaluated by a study doctor if you choose to continue with screening for the study.
Check Your Eligibility
Why Should I join the I CAN Study?
By enrolling in this phase 3 study, you may receive:
Individualized attention from a dedicated medical team with experience managing IgA nephropathy
Access to a potential treatment option, ravulizumab, at no cost to you.
Ravulizumab is being studied to find out if it can ease stress on the kidneys in people with IgAN by lowering protein in their urine and helping their kidneys work better for longer.
Participants may receive travel reimbursement, compensation for their time and study visits, and medical monitoring and support throughout the study.
Your participation may support the advancement of treatments for individuals with IgA nephropathy.
Take The First Step
What Should I Expect?
/01
Submit Online Questionnaire
This questionnaire will ask for your contact information and a few questions about your medical history to determine your eligibility.
Then, select a time for a short phone call with PatientWing. Submitting the questionnaire is voluntary and does not require a commitment to participate in the study.
/02
Speak With PatientWing
PatientWing is partnering with Alexion to help identify potential individuals who may be interested in the I CAN study.
You will have a short call to answer additional questions about your medical history, and PatientWing will help collect your medical records.
/03
Speak With the Study Team
After your conversation with PatientWing, you will meet the study team who will review your medical records. The study team will provide more information during your conversations with them. No question is a bad question so please share your concerns with the team!
The screening period lasts approximately six weeks.
The study team will review your medical history and perform tests to see if you qualify for the study. If you qualify, your study doctor will make sure you are receiving renin-angiotensin system inhibitor (RASi, a medication that can help with kidney function) therapy for at least three months before study treatment may begin. You will continue taking RASi as background therapy throughout the study.
/04
Study Participation
Study participation lasts approximately two years and includes 15 visits to the study site.
You should expect the following:
You will be randomly assigned to receive either the study drug or a placebo through an IV (intravenous) infusion every 8 weeks.
The average visit will last roughly 3 to 4 hours with approximately 30 to 60 minutes for the infusion of ravulizumab or placebo.
A placebo looks just like the study drug but contains no active ingredients.
/05
Open-Label Extension
This study includes an optional extension period, during which the placebo will be removed, and all participants will receive the study drug. Open-label means you and the study team will know that the study drug (ravulizumab) is being given.
Learn About
IgA Nephropathy (IgAN) 
IgAN is a rare kidney disease that affects how well the kidneys filter blood. Over time, it may cause the kidneys to work less effectively. IgAN causes protein to leak into urine, which is called proteinuria.
Proteinuria means that higher amounts of protein are leaving your body through your urine. It can sometimes make your urine look foamy.
Not everyone with IgAN notices their symptoms right away.
Possible signs may include:
Foamy or tea-colored urine
Swelling in feet, ankles, or eyelids (known as “edema”)
High blood pressure
Tiredness or back pain
Doctors often use routine urine and blood tests to check:
Protein in urine (proteinuria)
Kidney function (eGFR test)
Blood pressure
These tests help track changes in kidney health over time. Even if you feel well, IgAN can progress quietly. Regular check-ins with your doctor can help manage your IgAN disease.
Talk with your doctor about the I CAN Study and if it may be a good fit for you.
Fill Out The Questionnaire

Frequently Asked Questions

Contact Us
How do I get started?
Complete the questionnaire and enter your information to express interest in the study. You can also email studies@patientwing.com or call 213-459-2979.
How will the study drug be taken?
The study drug and/or the placebo will be given via IV infusion every 8 weeks. You will have 15 visits to the research site during the 2-year (106-week) study period.
Is there any cost for me to participate?
There is no cost to participate in this clinical study. All study related material including ravulizumab or placebo, study visits, tests and examinations are free of charge to you and will be covered by the study sponsor.
You can talk to the research site staff about travel arrangements and expense-related reimbursements.
Will I receive compensation if I participate in this study?
Yes, you will receive visit stipends for participating in the study. The study coordinator can provide you with specific information about the compensation, but it may range from $74 to $111 per visit, depending on the activities performed.
How is the study drug, ravulizumab, designed to work?
Ravulizumab will be given by an intravenous (IV) infusion once every 8 weeks for just over 2 years, resulting in 15 study visits and 1 one screening visit.
Ravulizumab works by blocking a part of your immune system (the complement system) that can harm the kidneys in people with IgAN. By targeting the C5 protein, the study drug may reduce inflammation and prevent further kidney damage.
Has the study drug been tested before?
Ravulizumab has been investigated in a Phase 2 study of adults with IgAN. This study did not show any safety concerns and indicated improvements in kidney function. These findings are now being confirmed in this Phase 3 study.
Is there a chance I will receive a placebo?
Yes, this study has a 50% chance of receiving a placebo.
About the Sponsor
Alexion's mission is to discover, develop, and deliver innovative therapies that target the underlying cause of diseases, providing hope and a better quality of life for patients who have limited or no treatment options.
About PatientWing
Our mission to bring better treatments to more people faster starts with you. We help sponsors find patients to participate in their clinical studies. With our focus on rare and serious conditions and expertise in navigating the enrollment process, we're here for you every step of the way.
Have Questions?
At PatientWing, we’re here to support you at every step of the study. You can email, text, call or fill out the form with any questions.
Email
studies@patientwing.com
Phone
213-459-2979
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Stay Connected
Receive marketing communications from PatientWing such as patient stories and relevant clinical trial opportunities.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.